Financial Performance - For the first quarter ended March 31, 2023, the company reported a revenue of RMB 100,553,000, representing a decrease of 79.86% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of RMB 139,547,000, reflecting a decline of 214.94% year-over-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 179,076,000, down 317.82% from the previous year[4] - The basic and diluted earnings per share were both RMB (0.57), a decrease of 216.33% compared to the same period last year[4] - Total revenue for Q1 2023 was RMB 100,553 thousand, a decrease of 79.9% compared to RMB 499,355 thousand in Q1 2022[16] - Net profit for Q1 2023 was a loss of RMB 170,199 thousand, compared to a profit of RMB 114,295 thousand in Q1 2022, indicating a significant decline[17] - Basic earnings per share for Q1 2023 were RMB (0.57), compared to RMB 0.49 in Q1 2022, indicating a significant decline in profitability[18] - The total comprehensive income for Q1 2023 was a loss of RMB (170,166) thousand, compared to a profit of RMB 114,295 thousand in Q1 2022, showing a significant downturn[18] Assets and Liabilities - The total assets at the end of the reporting period were RMB 11,215,389,000, a decrease of 2.21% from the end of the previous year[5] - The company's current liabilities decreased to RMB 2,620,183,000 from RMB 2,924,708,000 as of December 31, 2022, indicating improved liquidity[14] - The total liabilities as of March 31, 2023, were RMB 4,137,354 thousand, a decrease from RMB 4,223,358 thousand as of December 31, 2022, reflecting a reduction of 2.0%[15] - The total equity as of March 31, 2023, was RMB 7,078,035 thousand, down from RMB 7,245,602 thousand as of December 31, 2022, a decrease of 2.3%[15] Research and Development - Research and development expenses totaled RMB 150,871,000, representing a decrease of 5.36% year-over-year[4] - The proportion of R&D expenses to operating income was 150.04%, indicating an increase of 118.12 percentage points compared to the previous year[4] - Research and development expenses for Q1 2023 were RMB 149,765 thousand, slightly down from RMB 157,155 thousand in Q1 2022, a decrease of 4.4%[16] Cash Flow and Investments - In Q1 2023, the net cash flow from operating activities was (CNY 345,404,000), a significant improvement from (CNY 598,148,000) in Q1 2022, indicating a reduction in cash outflow[20] - Total cash inflow from investment activities in Q1 2023 was CNY 2,787,236,000, compared to CNY 2,135,294,000 in Q1 2022, reflecting a year-over-year increase of approximately 30.6%[21] - The net cash flow from investment activities was (CNY 172,009,000) in Q1 2023, an improvement from (CNY 894,010,000) in Q1 2022, showing a reduced cash outflow[21] - The cash and cash equivalents at the end of Q1 2023 stood at CNY 2,843,894,000, down from CNY 3,973,871,000 at the end of Q1 2022, representing a decrease of approximately 28.5%[23] - The cash outflow from operating activities totaled CNY 485,702,000 in Q1 2023, down from CNY 828,517,000 in Q1 2022, indicating improved operational efficiency[20] Inventory and Shareholder Information - The total inventory increased to RMB 788,349,000 from RMB 677,777,000, reflecting a 16.3% rise, which may indicate increased production or anticipated sales[12] - The company had a total of 23,808 common shareholders at the end of the reporting period[7] Strategic Initiatives - The company plans to issue Global Depository Receipts (GDRs) and list them on the Swiss Stock Exchange to enhance international financing channels[10] - The company is actively pursuing an internationalization strategy to enhance its brand and image[10] Other Financial Metrics - Other income for Q1 2023 was RMB 33,379 thousand, an increase of 50.0% from RMB 22,297 thousand in Q1 2022[17] - The company reported a credit impairment loss of RMB (11,181) thousand in Q1 2023, compared to RMB (3,143) thousand in Q1 2022, indicating a worsening situation[17] - The impact of exchange rate changes on cash and cash equivalents was (CNY 19,486,000) in Q1 2023, compared to (CNY 12,150,000) in Q1 2022, indicating increased volatility[23] - The total cash inflow from other investment activities was CNY 69,583,000 in Q1 2023, with no comparable figure reported for Q1 2022[21] - The company did not report any cash inflow from financing activities in Q1 2023, indicating a focus on internal funding sources[21]
康希诺生物(06185) - 2023 Q1 - 季度业绩